about
Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project DatabaPeripheral T-cell lymphoma, unspecified--the analysis of the data from the Czech Lymphoma Study Group (CLSG) registry.Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia.Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.A new prognostic score for elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: the prognostic role of blood monocyte and lymphocyte counts is absentRituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia.Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma.Frontline intensive chemotherapy improves outcome in young, high-risk patients with follicular lymphoma: pair-matched analysis from the Czech Lymphoma Study Group Database.Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study.[Lymphomatoid granulomatosis - the past and present].Venous thromboembolism in patients with chronic lymphocytic leukemia.Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database.Severe anemia caused by combination of autoimmune hemolysis, pure red cell aplasia and massive bone marrow infiltration in an elderly patient with chronic lymphocytic leukemia: successful treatment with rituximab.Cutaneous natural killer (NK) / T-cell lymphoma: nasal type with extensive facial destruction.Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial.Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: is it time to change the standard strategy?Addition of rituximab significantly improves outcomes in patients with diffuse large B-cell lymphoma--a single-center, retrospective study.Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study.Addition of Rituximab Significantly Improves Outcomes in Patients with Diffuse Large B-cell Lymphoma - a Single-center, Retrospective Study.Trimodality imaging of colonic lymphoma.[Primary testicular lymphoma].Tumorous neo-vascularization: a newly recognized endoscopic feature of intestinal non-Hodgkin lymphomaPrognostic relevance of angiopoietin-2, fibroblast growth factor-2 and endoglin mRNA expressions in chronic lymphocytic leukemiaPlasma levels of basic fibroblast growth factor and vascular endothelial growth factor and their association with IgVH mutation status in patients with B-cell chronic lymphocytic leukemiaIntravascular large B-cell lymphoma presenting as cutaneous panniculitisDiffuse large B-cell lymphoma in a patient with hyper-IgE syndrome: Successful treatment with risk-adapted rituximab-based immunochemotherapyPre-transplant positron emission tomography in patients with relapsed Hodgkin lymphomaThe use of formalin-fixed, paraffin-embedded lymph node samples for the detection of minimal residual disease in mantle cell lymphomaTen years' experience with four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, procarbazine (BEACOPP)-escalated followed by four cycles of baseline-dose BEACOPP in patients with advanced stage Hodgkin lymphomNK/T-cell lymphoma nasal type with an unusual clinical courseDacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind,Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry
P50
Q30649483-6CB95C88-7849-40F0-A965-5F9119B19D1AQ31121474-422E3BCD-6E86-43A5-B763-C2739FC94C50Q33402561-8BB8FCD0-F352-469E-A012-79EBD64A0FB2Q33430165-29EB0B48-116A-426A-A192-B2F0924ABBAEQ33945770-86BBFA52-C617-40B7-8FD2-B31BD8DDC69AQ34156097-978E4E06-F2EB-4E59-8264-52B570BEC057Q36845282-96CBE012-5F99-4851-8274-74405F3AF3D9Q38878964-72E885BB-DB36-4787-8D05-A6631DAB4431Q39353147-72EE0CF0-B0A4-4438-AE67-8A7C9A620ADBQ40073860-2642C2F6-9311-4E82-9C11-4E4E576EA217Q40201704-C5393915-FC5B-421E-AF7C-FE8BCB940C8EQ40431314-C010F875-2E49-4BA9-A7E3-646B9EFDB529Q41465999-15377696-4781-43C6-8715-64AE2815A493Q43201314-85D5D660-8E15-4009-9CE7-FC59325B05F4Q43237510-B664F650-D9F1-4EB7-A6F0-92DE31CB31BCQ43930995-31765DC9-E185-4134-8841-D647758E2BA3Q46334893-CD219D86-4DA4-4671-8DC8-50C0FCE487B7Q46884431-F3F9F37C-58CC-474B-9D5D-AE2B88672748Q48897293-8FCAA51E-D3A0-44F8-8F53-ED48B5DC7496Q49823958-22139F11-FD37-43AD-80A8-0C49518653C9Q53369230-1149EF89-DCFC-49E0-B2AC-9FC9C5D9A3B6Q53747764-D129AEBA-61FB-4DFD-B02B-0B43F8E52765Q59653117-868DA7F0-EDAD-4E15-A78D-8C3B11C004F9Q62112104-86230ED2-40A5-4E5D-A141-452E65A703D6Q79181589-A56BE0A1-7180-4128-94FE-0755E1974774Q79369152-92D40A1A-1590-41AF-B73E-A8C63E800F3BQ83184674-A94079E8-756C-4A09-AB45-C991884E5051Q84431044-4711BBB3-9EE8-42DE-AAD7-9A4AF919AE83Q85779439-D78D57C0-A4DD-4092-8C70-D18EF0EA94F7Q85830551-B13783E2-2855-47AF-ADAD-DD9CCB7B6675Q85933995-D3F660CA-7865-4D78-BB80-A4F3A5D5CA85Q86657799-02726AC3-1F83-4EFC-9608-6A201FC63E65Q89228728-A0C13622-4577-4307-8914-9E59B6623DD1
P50
description
Czech hematologist
@en
wetenschapper
@nl
name
David Belada
@ast
David Belada
@cs
David Belada
@en
David Belada
@es
David Belada
@fr
David Belada
@nl
David Belada
@sk
type
label
David Belada
@ast
David Belada
@cs
David Belada
@en
David Belada
@es
David Belada
@fr
David Belada
@nl
David Belada
@sk
prefLabel
David Belada
@ast
David Belada
@cs
David Belada
@en
David Belada
@es
David Belada
@fr
David Belada
@nl
David Belada
@sk
P1153
14719140100
P21
P214
79149842078402842101
P31
P496
0000-0002-4981-6188
P569
1972-06-28T00:00:00Z
P691
mzk2006322730
P735
P7859
viaf-79149842078402842101